The global biologics sector is expanding rapidly as healthcare providers and pharmaceutical companies increasingly adopt targeted therapies. The sector is projected to reach USD 522.06 billion in 2026 and approximately USD 1,009.33 billion by 2035, growing at a CAGR of 7.6% from 2026 to 2035.
What Are Biologics?
Biologics are therapeutic products derived from living organisms or their components, including proteins, cells, and nucleic acids. Unlike conventional chemically synthesized medicines, biologics are produced using advanced biotechnology and can target specific biological pathways.
They are widely used to treat cancer, autoimmune disorders, infectious diseases, hematological conditions, and rare diseases. Their targeted mechanisms can improve treatment outcomes while potentially reducing unwanted effects.
Key Trends Driving Growth
The rising prevalence of chronic diseases is increasing demand for effective and personalized treatments. Biologics are playing an important role in oncology, immunology, and rare disease management.
Monoclonal antibodies accounted for 45% of the product segment in 2025, supported by their high specificity and broad use in cancer and immune-related treatments. Meanwhile, antisense and RNAi therapeutics are expected to experience rapid growth as innovative approaches for genetic and neurological disorders advance.
Artificial intelligence is also transforming biologics development. AI can analyze large biological datasets, identify promising therapeutic candidates, improve clinical trial recruitment, and optimize manufacturing processes.
Biosimilars Create New Opportunities
The growing adoption of biosimilars is another important trend. As patents for major biologic medicines expire, biosimilars can provide more affordable treatment options and increase patient access. Pharmaceutical companies are therefore investing in efficient development, manufacturing, and regulatory strategies.
Regional Outlook
North America accounted for 55% of the global share in 2025, supported by strong pharmaceutical companies, advanced research infrastructure, favorable reimbursement policies, and significant biotechnology investment.
Asia Pacific is expected to experience the fastest growth, driven by expanding biotechnology capabilities, government initiatives, increasing healthcare investment, and growing biosimilar development in countries such as China and India.
Download a Sample Report: https://www.towardshealthcare.com/download-sample/5108
Future Outlook
The future of biologics will be shaped by precision medicine, AI-powered drug development, biosimilars, advanced manufacturing, and emerging RNA-based therapies. Increasing investment in biotechnology and the growing need for targeted treatments are expected to support continued expansion through 2035.
About Us
Healthcare WebWire is a part of Towards Healthcare Research & Consulting is a global healthcare market research and consulting firm dedicated to helping businesses make informed decisions through reliable market intelligence and strategic insights. We serve pharmaceutical, biotechnology, medical device, AI in healthcare, cell and gene therapy, digital health, and life sciences organizations with in-depth market research, custom consulting, competitive analysis, and growth forecasts. Our team combines industry expertise with rigorous research to deliver clear, actionable insights that support market expansion, product strategy, investment decisions, and long-term business growth. From emerging innovations to established healthcare markets, we help organizations understand where the industry is today and where it’s headed tomorrow.
You can place an order or ask any questions, please feel free to contact us at [email protected]
Europe Region – +44 778 256 0738
North America Region – +1 8044 4193 44
APAC Region: +91 9356 9282 04
Visit Our Website: Towards Healthcare Research & Consulting – Expert Consulting Solutions & Research Reports
Find us on social platforms: LinkedIn | Twitter | Instagram | Medium